Challenges in Immunomodulation for Psoriasis: Recent Advancements and Need of Therapies

IF 0.3 Q4 PHARMACOLOGY & PHARMACY Current Drug Therapy Pub Date : 2023-11-24 DOI:10.2174/0115748855274998231113110529
Dilpreet Singh
{"title":"Challenges in Immunomodulation for Psoriasis: Recent Advancements and Need of Therapies","authors":"Dilpreet Singh","doi":"10.2174/0115748855274998231113110529","DOIUrl":null,"url":null,"abstract":"Psoriasis is a chronic immune-mediated skin disorder affecting millions worldwide. The pathogenesis of psoriasis involves dysregulated immune responses characterized by aberrant activation of T cells and proinflammatory cytokines. Immunomodulation has emerged as a promising therapeutic approach for managing psoriasis, aiming to restore immune homeostasis. However, despite significant advancements, challenges persist in developing effective immunomodulatory therapies. This abstract reviews recent developments in psoriasis immunomodulation, encompassing novel targets and therapeutic modalities. Advances in biologics targeting interleukins (IL) and their receptors, such as IL-17, IL-23, and IL-12/23, have demonstrated substantial clinical efficacy. Additionally, small molecules that inhibit Janus kinases (JAK) and phosphodiesterase 4 (PDE4) have shown promise in regulating immune responses. Despite these advancements, certain limitations hinder the success of immunomodulatory therapies. Treatment resistance, safety concerns, and high costs remain critical challenges. Furthermore, a deeper understanding of the complex immunopathogenesis of psoriasis is essential for developing targeted and personalized therapies. In conclusion, immunomodulation has revolutionized the management of psoriasis, offering remarkable improvements in patient outcomes. Continued research and innovative therapeutic strategies are needed to overcome current challenges and pave the way for more efficient, safe, and accessible treatments for psoriasis.","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748855274998231113110529","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Psoriasis is a chronic immune-mediated skin disorder affecting millions worldwide. The pathogenesis of psoriasis involves dysregulated immune responses characterized by aberrant activation of T cells and proinflammatory cytokines. Immunomodulation has emerged as a promising therapeutic approach for managing psoriasis, aiming to restore immune homeostasis. However, despite significant advancements, challenges persist in developing effective immunomodulatory therapies. This abstract reviews recent developments in psoriasis immunomodulation, encompassing novel targets and therapeutic modalities. Advances in biologics targeting interleukins (IL) and their receptors, such as IL-17, IL-23, and IL-12/23, have demonstrated substantial clinical efficacy. Additionally, small molecules that inhibit Janus kinases (JAK) and phosphodiesterase 4 (PDE4) have shown promise in regulating immune responses. Despite these advancements, certain limitations hinder the success of immunomodulatory therapies. Treatment resistance, safety concerns, and high costs remain critical challenges. Furthermore, a deeper understanding of the complex immunopathogenesis of psoriasis is essential for developing targeted and personalized therapies. In conclusion, immunomodulation has revolutionized the management of psoriasis, offering remarkable improvements in patient outcomes. Continued research and innovative therapeutic strategies are needed to overcome current challenges and pave the way for more efficient, safe, and accessible treatments for psoriasis.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
银屑病免疫调节疗法面临的挑战:最新进展和治疗需求
银屑病是一种由免疫介导的慢性皮肤病,影响着全球数百万人。银屑病的发病机制涉及以 T 细胞异常激活和促炎细胞因子为特征的免疫反应失调。免疫调节已成为治疗银屑病的一种很有前景的方法,其目的是恢复免疫平衡。然而,尽管取得了重大进展,但开发有效的免疫调节疗法仍面临挑战。本摘要回顾了银屑病免疫调节的最新进展,包括新的靶点和治疗模式。以白细胞介素(IL)及其受体(如IL-17、IL-23和IL-12/23)为靶点的生物制剂取得的进展已显示出巨大的临床疗效。此外,抑制 Janus 激酶 (JAK) 和磷酸二酯酶 4 (PDE4) 的小分子药物也显示出调节免疫反应的前景。尽管取得了这些进展,但某些局限性阻碍了免疫调节疗法的成功。耐药性、安全性问题和高昂的成本仍然是严峻的挑战。此外,深入了解银屑病复杂的免疫发病机制对于开发靶向和个性化疗法至关重要。总之,免疫调节已彻底改变了银屑病的治疗方法,显著改善了患者的治疗效果。我们需要继续研究和创新治疗策略,以克服当前的挑战,并为银屑病的更高效、更安全和更易获得的治疗铺平道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Drug Therapy
Current Drug Therapy PHARMACOLOGY & PHARMACY-
CiteScore
1.30
自引率
0.00%
发文量
50
期刊介绍: Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.
期刊最新文献
Revolutionizing Healthcare and Drug Discovery: The Impact of Artificial Intelligence on Pharmaceutical Development Advancements in Natural Alkaloid-Loaded Drug Delivery Systems for Enhanced Peptic Ulcer Treatment: A Review Internet of Healthcare Things Based Detection of EEG Epileptic Seizures: A Smart System Exploring the Potential of Pectin for Gastro Retentive Drug Delivery Systems: From Orchard to Drug Delivery Gold Nanoparticles: An Emerging Novel Technology for Targeted Delivery System for Site-Specific Diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1